Apogee Therapeutics, Inc. (NasdaqGM: APGE) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Apogee will receive $135.11 in cash for each share of Apogee that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.